Med A Eye Mammo

Med * A-Eye Mammogram analyser

Free · Designed for iPad

The Med * A-Eye mammogram analyzer is an experimental system that scans mammograms and identifies regions of possible diagnostic interest for review by medical professionals. The Med * A-Eye mammogram analyzer does not offer medical or diagnostic advice. There are no accuracy claims associated with the app, and users may delete their data and the account from the app. The mammogram analyzer is provided “as is” with no representation or warranty of any kind, express or implied, regarding the accuracy, adequacy, validity, reliability, or completeness of any information furnished to you, including any warranty of merchantability or fitness for a particular purpose.

  • This app hasn’t received enough ratings or reviews to display an overview.

1. User decides which files to download 2. Fixed bug to restart interrupted download 3. Download status displayed to user

The developer, Art Eye-D Associates, indicated that the app’s privacy practices may include handling of data as described below. For more information, see the developer’s privacy policy .

  • Data Not Collected

    The developer does not collect any data from this app.

    Privacy practices may vary, for example, based on the features you use or your age. Learn More

    The developer has not yet indicated which accessibility features this app supports. Learn More

    • Seller
      • Art Eye-D Associates LLC
    • Size
      • 158.7 MB
    • Category
      • Medical
    • Compatibility
      Requires iOS 14.0 or later.
      • iPhone
        Requires iOS 14.0 or later.
      • iPad
        Requires iPadOS 14.0 or later.
      • iPod touch
        Requires iOS 14.0 or later.
      • Mac
        Requires macOS 11.0 or later and a Mac with Apple M1 chip or later.
      • Apple Vision
        Requires visionOS 1.0 or later.
    • Languages
      • English
    • Age Rating
      13+
      • 13+
      • Infrequent
        Medical Treatment information
    • Copyright
      • © 2023-2024